Abstract
Isha Saini, Sukhbir Kaur
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unwelcome prevalence of leishmaniasis with several other infectious diseases
10.1016/j.intimp.2022.109059 · 2022
Leishmaniasis: Recent epidemiological studies in the Middle East
10.3389/fmicb.2022.1052478 · 2023
Visceral leishmaniasis: Epidemiology, diagnosis, and treatment regimens in different geographical areas with a focus on pediatrics
10.3390/microorganisms10101887 · 2022
Leishmania vaccine development: A comprehensive review
10.1016/j.cellimm.2024.104826 · 2024
Immune responses in leishmaniasis: an overview
10.3390/tropicalmed7040054 · 2022
Leishmaniasis: immune cells crosstalk in macrophage polarization
10.3390/tropicalmed8050276 · 2023
Memory T cells in cutaneous leishmaniasis
10.1016/j.cellimm.2016.07.010 · 2016
Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis
10.3389/fimmu.2024.1304696 · 2024
Central and effector memory human CD4+ and CD8+ T cells during cutaneous leishmaniasis and after in vitro stimulation with Leishmania (Viannia) braziliensis epitopes
10.3390/vaccines11010158 · 2023
Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice
10.1371/journal.pone.0204491 · 2018
First generation leishmaniasis vaccines: a review of field efficacy trials
10.1016/j.vaccine.2008.09.085 · 2008
Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis
10.1016/j.parint.2009.07.008 · 2009
Unleashing the role of potential adjuvants in leishmaniasis
10.1016/j.ijpharm.2024.125077 · 2025
The steroidal alkaloids α-tomatine and tomatidine: Panorama of their mode of action and pharmacological properties
10.1016/j.steroids.2021.108933 · 2021
Immunobiology of the tomatine adjuvant
10.1016/j.vaccine.2004.03.022 · 2004
10.1515/bc-2011-222
10.1515/bc-2011-222
Evaluation of antileishmanial efficacy of Salidroside against the SSG-sensitive and resistant strain of Leishmania donovani
10.1016/j.parint.2019.101928 · 2019
Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB/c mice
10.1016/j.micpath.2021.105021 · 2021
Enhanced efficacy and immunogenicity of 78ákDa antigen formulated in various adjuvants against murine visceral leishmaniasis
10.1016/j.vaccine.2010.01.015 · 2010
Adjuvant effects of Astragalus saponins macrophyllosaponin B and astragaloside VII
10.1016/j.jep.2011.01.054 · 2011
Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: a new promising vaccine against visceral leishmaniasis
10.1016/j.vaccine.2020.11.064 · 2021
Efficacy of LaAg vaccine associated with saponin against Leishmania amazonensis infection
10.3390/vaccines13020129 · 2025
Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice
1977
Immunotherapeutic potential of Codonopsis clematidea and naringenin against visceral leishmaniasis
10.1016/j.biopha.2018.09.104 · 2018
CD8+ T cells are preferentially activated during primary low dose Leishmania major infection but are completely dispensable during secondary anti-Leishmania immunity
10.1371/journal.pntd.0003300 · 2014
Lupeol induces immunity and protective efficacy in a murine model against visceral leishmaniasis
10.1017/s0031182019000659 · 2019
Mahanine exerts in vitro and in vivo antileishmanial activity by modulation of redox homeostasis
10.1038/s41598-017-03943-y · 2017
Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice
10.1016/j.imbio.2021.152057 · 2021
Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method
10.1006/meth.2001.1262 · 2001
Paradoxical immune response in leishmaniasis: The role of toll-like receptors in disease progression
10.1111/pim.12910 · 2022
Chimeric vaccines designed by immunoinformatics-activated polyfunctional and memory T cells that trigger protection against experimental visceral leishmaniasis
10.3390/vaccines8020252 · 2020
A recombinant chimeric protein-based vaccine containing T-cell epitopes from amastigote proteins and combined with distinct adjuvants, induces immunogenicity and protection against leishmania infantum infection
10.3390/vaccines10071146 · 2022
Activity of rutin, a potent flavonoid against SSG-sensitive and-resistant Leishmania donovani parasites in experimental leishmaniasis
10.1016/j.intimp.2018.09.026 · 2018
Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research
10.1016/j.biopha.2021.111671 · 2021
IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine
10.1186/1471-2180-14-8 · 2014
Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis
10.1016/j.meegid.2019.01.005 · 2019
Neutrophils and Visceral Leishmaniasis: Impact on innate immune response and cross-talks with macrophages and dendritic cells
10.1002/jcp.30029 · 2021
Elucidating the mechanisms of action of saponin-derived adjuvants
10.1016/j.tips.2018.03.005 · 2018
Therapy with radio-attenuated vaccine in experimental murine visceral leishmaniasis showed enhanced T cell and inducible nitric oxide synthase levels, suppressed tumor growth factor-beta production with higher expression of some signaling molecules
10.1016/j.bjid.2014.10.009 · 2015
Host–pathogen interaction in leishmaniasis: immune response and vaccination strategies
10.3390/immuno2010015 · 2022
Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis
10.1007/s00253-022-12033-7 · doi-reference
Long-lived skin-resident memory T cells contribute to concomitant immunity in cutaneous leishmaniasis
10.1101/cshperspect.a038059 · doi-reference
Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites
10.1038/nm1108 · doi-reference
10.1146/annurev.immunol.20.100101.151926
10.1146/annurev.immunol.20.100101.151926 · doi-reference
Deciphering the relationship between central and effector memory CD8+ T cells
10.1016/s1471-4906(03)00169-8 · doi-reference
Central memory and effector memory T cell subsets: function, generation, and maintenance
10.1146/annurev.immunol.22.012703.104702 · doi-reference
Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review
10.1016/j.phymed.2019.152905 · doi-reference
High Selectivity of 8-Hydroxyquinoline on Leishmania (Leishmania) and Leishmania (Viannia) Species Correlates with a Potent Therapeutic Activity In Vivo
10.3390/ph16050707 · doi-reference